Corporate News

Concepta PLC (AIM: CPT), the personalised healthcare company, announces the appointment of Oberon Capital, part of the Oberon Investments Ltd group, as joint broker with immediate effect.

About Concepta PLC ( www.conceptaplc.com )

Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product MYLO, targeted at the personalized mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained infertility.

MYLO is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of MYLO   is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.

The Company has received CE-mark certification for MYLO and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2020 and 2021.

MYLO is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.